Live Breaking News & Updates on Intestinal Cancer Trials Group

Stay updated with breaking news from Intestinal cancer trials group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United States , New South Wales , New Zealand , John Menditto , Robert Leboyer , Pete Enderlin , Erkki Ruoslahti , David Mazzo , James Nisco , Robert Sassoon , Joseph Pantginis , Steve Brozak , Sara Nik , Therapeutic Goods Administration , Clinical Trial Center , Therapeutic Goods Regulatory Agency Of The Australian , Water Tower Research , Exchange Commission , University Of Sydney , Data Safety Monitoring Committee , Intestinal Cancer Trials Group , European Union , Corporate Communications , International Nonproprietary Name , Cendr Platform Technology , Lisata Therapeutics Inc ,

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Earnings Call Transcript

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Earnings Call Transcript August 17, 2023 Operator: Welcome to the Lisata Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following managements’ prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, the call is being […] ....

United States , New South Wales , New Zealand , Intestinal Cancer Trials Group , University Of Sydney , Drug Administration , Chief Medical Officer , Kristen Buck , Cendc End , Qilu Pharmaceutical , Glioblastoma Multiforme , Solid Tumors , Lisata Therapeutics , Financial Results , James Nisco , Solid Tumors , Tumor Microenvironment , John Menditto , Chief Medical Officer , David Mazzo , Clinical Development , Clinical Trials ,

Lisata Therapeutics, Inc. (LSTA) Q3 2022 Earnings Call Transcript

Lisata Therapeutics, Inc. (NASDAQ:NASDAQ:LSTA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants John Menditto - VP, IR and Corporate Communications Dave. ....

United States , Roche Genentech , David Mazzo , John Menditto , David Slack , Peter Enderlin , Shubhendu Roy , James Nisco , Dave Mazzo , Company Participants , Drug Administration , Exchange Commission , Japanese Pharmaceuticals , Corporate Communications , Intestinal Cancer Trials Group , Corporate Communications At Lisata , Devices Agency , Lisata Therapeutics Inc , Lisata Therapeutics , Conference Call November , Chief Business , Chief Medical , Lisata Therapeutics Third Quarter , Business Update Conference , Vice President , Investor Relations ,

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (NASDAQ:NASDAQ:CLBS) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David. ....

United States , New Zealand , New South Wales , Kumar Raja , David Mazzo , John Menditto , Pete Enderlin , James Nisco , Caladrius Biosciences , Company Participants , Caladrius Biosciences Inc , National Health , Corporate Communications At Caladrius , Ir Corporate Communications , University Of Sydney , Exchange Commission , Research Council Clinical Trial Center , Japanese Pharmaceuticals , Intestinal Cancer Trials Group , Devices Agency , Conference Call August , Caladrius Bioscience Second Quarter , Business Update Conference , Vice President , Investor Relations , Corporate Communications ,